Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Bromantane (Ladasten)
Beginner tier: 25 mg, daily · 4w on / 3w off · clinical trials
Also known as: Ladasten, Bromantane, ADK-709
In an uncontrolled 728-patient Russian multicenter study of asthenic disorders, 90.8% were CGI-I responders on bromantane at 50 to 100 mg daily, with adverse events in just 3% [1]. Bromantane (Ladasten) is a synthetic actoprotector that upregulates dopamine synthesis enzymes rather than flooding synapses like traditional stimulants. No Western clinical trials exist, and WADA prohibits it in competition as a non-specified stimulant (S6.A). Biohackers and nootropic users value it for calm, sustained motivation without the crash or jitter that comes with amphetamine-class compounds. Most users cycle 4 weeks on.
What Is Bromantane (Ladasten)?
90.8% of 728 patients were rated as responders on the CGI-I scale. That number comes from an uncontrolled Russian multicenter study of asthenic disorders [1], with no placebo arm, at 50 to 100 mg daily over 28 days. Adverse events hit only 3% of participants. A separate placebo-controlled trial in neurasthenia found faster and larger symptom relief than placebo [6].
Bromantane (N-(4-bromophenyl)adamantan-2-amine, also sold as Ladasten) sits on an adamantane scaffold, the same carbon cage behind amantadine and memantine. Russia registered it in 2008 for asthenic conditions and neurasthenia. The compound first hit international radar when athletes at the 1996 Atlanta Olympics tested positive for it.
What separates bromantane from stimulants like modafinil or amphetamines is the mechanism. It doesn't block dopamine reuptake. It doesn't dump monoamines into synapses. Instead, it upregulates tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD), the two rate-limiting enzymes in dopamine production. In rats, a single dose more than doubled TH mRNA in the hypothalamus within 1.5 to 2 hours [4]. The result is a gradual, sustained lift in dopamine synthesis rather than a spike and crash.
Community experience across several hundred documented reports on r/nootropics and peptide forums lines up closely with the clinical data. Users consistently describe calm energy, improved task initiation, and better physical stamina. Effects build over the first week; judging bromantane after a single dose misses the point entirely.
Western clinical evidence is thin. No FDA-reviewed trials exist. No English-language double-blind placebo-controlled studies have been published. Most pharmacological data traces back to Russian-language journals or preclinical animal work. That gap is real, and it matters for anyone weighing risk.
How Bromantane (Ladasten) Works
Bromantane's primary action is indirect genomic upregulation of dopamine biosynthesis. It increases transcription of tyrosine hydroxylase (TH) mRNA and protein in the hypothalamus, striatum, ventral tegmental area, and nucleus accumbens. It also upregulates aromatic L-amino acid decarboxylase (AAAD), the enzyme converting L-DOPA into dopamine. Together, these increases produce more dopamine without the reuptake inhibition or vesicular dumping of traditional stimulants.
The timeline matters. In rats, TH mRNA in the hypothalamus more than doubles within 1.5 to 2 hours of a single dose [4]. Those rat studies used 50 mg/kg by mouth [2]. This genomic mechanism is why effects build over days of consistent dosing. It also accounts for the low abuse potential; there's no immediate dopamine surge, just a steady upward shift in baseline synthesis capacity.
On the anxiolytic side, bromantane strengthens GABA-ergic neurotransmission. The exact molecular target hasn't been fully characterized. It doesn't appear to act on GABA-A benzodiazepine binding sites directly. So you get anxiolytic properties without the sedation, cognitive fog, or dependence risk tied to benzodiazepines.
Bromantane also increases expression of BDNF and NGF in certain brain regions (animal data). Those neurotrophic effects could contribute to the cognitive improvements reported with longer use, though human confirmation is sparse. Pharmacokinetically, oral bioavailability sits at approximately 42%. Peak plasma hits around 2.75 hours in females, roughly 4 hours in males. The compound is highly lipophilic and distributes into adipose tissue, which is why its primary metabolite (6-beta-hydroxybromantane) shows up in urine for up to two weeks after a single dose.
Bromantane (Ladasten) Benefits
- Bromantane benefits center on sustained dopaminergic drive and calm focus without stimulant-class side effects.
- Upregulates TH and AAAD enzymes to increase dopamine production at the source, rather than depleting existing stores the way amphetamines do. This distinction matters for long-term use.
- Combines mild stimulant and anxiolytic effects in one compound. Users consistently describe calm energy without jitteriness, a profile distinct from modafinil (tunnel vision) and racetams (purely cognitive).
- Improved physical work capacity and endurance under stress. Bromantane was developed as an actoprotector, a drug class designed to boost physical output without the metabolic cost of classical stimulants [3].
- Rapid onset with long-lasting activity. In rats, TH gene activity rises within 1.5 to 2 hours of one dose [4]. Community reports describe effects lasting 8 to 12 hours.
- No tolerance or dependence observed at 50 to 100 mg daily in available clinical and community data. The Russian 28-day trial confirmed consistent efficacy throughout the cycle.
- Raised BDNF and NGF gene expression in rat brain after a single dose [5], a possible neuroplasticity effect not yet tested in humans.
Bromantane (Ladasten): Science vs Community Consensus
Registered in Russia (Ladasten) for asthenic conditions and neurasthenia; the label gives 50-100 mg per dose, 100-200 mg/day in two doses, for 2-4 weeks (Vidal).
Read the evidence (key study, limitations)
Large uncontrolled multicenter study (728 patients with asthenic disorders, no placebo arm) reported 90.8% CGI-I responders [1]. A smaller placebo-controlled neurasthenia trial found bromantane superior to placebo [6]. Mechanism (TH/AAAD upregulation → dopamine synthesis) is well-characterized in preclinical models. No Western RCTs, no FDA-reviewed trials, no English-language double-blind placebo-controlled data.
PMID 21322821 (2010): uncontrolled multicenter study, 728 patients with asthenic disorders, 50-100 mg/day x 28 days, 90.8% CGI-I responders, 3% adverse event rate. Placebo-controlled neurasthenia trial: PMID 19491814 (2009).
All clinical evidence from Russian-language publications. No independent replication in Western trials. Long-term safety data (beyond 28-day cycle) absent from controlled data. No dose-ranging RCT comparing 50 mg vs 100 mg outcomes. Zero new PubMed publications 2024-2026.
Positive consensus.
Read the reports (what users report 6, common issues 6)
Valued for calm, sustained dopaminergic drive without jitteriness. More useful for physical/work output than pure cognition. Effects build over 5-7 days; first-week assessment discouraged.
- Calm energy without stimulant jitter or crash
- Improved physical stamina and work capacity
- Reduced background anxiety while maintaining drive
- Effects build over the first week: not a one-day compound
- Distinct from modafinil (no tunnel vision) and racetams (not purely cognitive)
- No crash or rebound at end of day
- Insomnia if taken after noon: most common complaint, dose-independent
- Mydriasis (pupil dilation) at standard doses noted by some users
- Tension headaches at doses above 150 mg
- Some long-term users report diminishing returns; conflicts with clinical data showing no tolerance
- GI upset (loose stools) at higher doses
- Effects too subtle for users expecting stimulant-class response
Both science and community converge on 50-100 mg/day oral dosing. Clinical efficacy matches community reports of improved energy, motivation, and stress tolerance. Community cycling pattern (4 weeks on/off) aligns with clinical trial duration (28 days). No significant divergence in dose or expected benefits.
Bromantane (Ladasten) Dosage Guide
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 25 mg | Daily |
| Moderate | 50 mg | Daily |
| Aggressive | 100 mg | Daily |
Bromantane is oral. No reconstitution, no syringes, no bacteriostatic water. You're working with either pre-made capsules or raw powder.
If you're dosing raw powder, a milligram-accurate scale (0.001 g resolution) is non-negotiable. A kitchen scale won't cut it for 25 to 50 mg doses. Weigh each dose individually or pre-weigh a batch into gelatin capsules.
Pre-measured research-chemical capsules eliminate the weighing hassle. Capsule dosing accuracy depends entirely on the manufacturing process; always check the third-party COA.
A small fatty meal before dosing may improve absorption. Bromantane's oral bioavailability is roughly 42% with significant first-pass metabolism. Fat helps lipophilic compounds cross the gut lining.
Morning dosing only. The 8 to 12 hour activity window means anything after noon puts your sleep at risk. Start at 25 mg for the first week. Don't judge effects until day 7 at minimum; the TH/AAAD genomic mechanism takes time to ramp.
Cycle 4 weeks on, 2 to 4 weeks off. The cycling isn't about tolerance (clinical data shows none) but about lipophilic accumulation in adipose tissue.
Cycling Protocol
The Russian label sets a 2-4 week course (Vidal), and the 728-patient study dosed for 28 days (PMID 21322821). Neither sets a break length. The 3 weeks off shown here is the middle of the 2-4 weeks off that community reports describe. Some users run shorter 2-week cycles. Due to lipophilic accumulation in adipose tissue, taking breaks is important even though acute tolerance doesn't appear to develop. Avoid stacking with other dopaminergic compounds during use.
Primary cycling rationale is lipophilic tissue accumulation, not receptor desensitization or hormonal axis suppression. Bromantane distributes extensively into adipose tissue due to high lipophilicity. With daily dosing, tissue levels build throughout a 4-week cycle. Extended continuous use risks progressive accumulation, particularly hepatic, beyond what the 28-day clinical trial safety data covers. Secondary rationale: the main Russian studies ran 28 days (PMID 21322821, PMID 19491814), and the Russian label sets a 2-4 week course. Clinical data shows no acute tolerance development.
- Diminishing motivational or energy effect despite consistent dosing (suggests accumulation-related saturation)
- Elevated ALT/AST at end-of-cycle bloodwork
- Persistent insomnia not explained by dosing timing
- Prolonged WADA detection window compared to expected clearance (indirect marker of adipose accumulation)
Or use the universal Peptide Calculator for any peptide.
Bromantane (Ladasten) Protocols by Goal
Expected: Improved motivation, sustained energy, reduced stress reactivity. Cognitive benefits secondary to motivational improvement.
Monitor: Track sleep quality: insomnia is the first flag. Consider baseline and end-of-cycle liver enzymes (ALT/AST) given lipophilic hepatic load.
How to Use Bromantane (Ladasten)
- 1Weigh your dose on a milligram-accurate scale (0.001 g)
If using pre-made capsules, skip to step 3. For a 50 mg dose with raw powder, the scale should read 0.050 g.
- 2Step 2
Place the weighed powder into an empty gelatin capsule or dissolve sublingually. Sublingual is reported to have faster onset, but no bioavailability data exists for that route.
- 3Take the dose in the morning, ideally before 9:00 AM
Pair with a small meal containing fat (eggs, avocado, nuts) to support absorption.
- 4Start at 25 mg daily for the first 5 to 7 days
If tolerated with no insomnia or headache, increase to 50 mg daily.
- 5Step 5
After 1 to 2 weeks at 50 mg, you can increase to 100 mg daily if more drive is needed. Do not exceed 100 mg without medical supervision.
- 6Run the cycle for 4 weeks total
Some users taper to 50 mg in the final 3 to 4 days, though no clinical data requires a taper.
- 7Take 2 to 4 weeks off between cycles
Effects taper gradually over 3 to 7 days after the last dose due to adipose tissue release.
Storage: powder and tablets are stable at room temperature (15 to 25 degrees C). For long-term storage of bulk powder, refrigerate at 2 to 8 degrees C.
Alternative Routes
Reference bioavailability (~42%)
Standard administration. Can be taken with or without food; small fatty meal may increase absorption given high lipophilicity. Pre-measured capsules reduce dosing error.
Potentially faster onset; bioavailability difference vs. oral is unknown
Community-reported faster onset when powder is dissolved sublingually. No pharmacokinetic data comparing sublingual to oral for bromantane. Taste is reportedly bitter/chemical. Not recommended over oral without supporting data.
Bromantane (Ladasten) Stacking Protocols
Works With
Complementary BDNF upregulation and ACTH-derived cognitive pathway. Semax provides immediate BDNF/focus via intranasal route while bromantane builds dopamine synthesis capacity over days. Mechanistically independent: no pharmacokinetic interaction documented.
Semax 400-600 mcg intranasal AM + Bromantane 50-100 mg oral AM
Anxiolytic balance. Selank modulates GABAergic activity and reduces anxiety without sedation, complementing bromantane's stimulant-adjacent activation. Core component of the "Russian cognitive triad."
Selank 250-500 mcg intranasal + Bromantane 50-100 mg oral
GI protection and systemic neuroprotection. No direct interaction with bromantane. Stacked for gut protection given GI side effects at higher bromantane doses, and for general recovery support.
BPC-157 250 mcg AM + PM on standard protocol; bromantane AM
Higher-potency Semax variant. Provides stronger BDNF effect at lower intranasal dose. Preferred by some users in the cognitive triad stack who find standard Semax underwhelming.
NA-Semax 100-200 mcg intranasal + Bromantane 50-100 mg oral
Avoid
Bromantane increases dopamine synthesis; MAO inhibition prevents dopamine breakdown. Combined effect could produce excessive dopaminergic stimulation: agitation, hyperthermia, cardiovascular stress.
Do not combineAdditive dopamine-enhancing effects. Bromantane upregulates synthesis enzymes; L-DOPA provides direct precursor loading. Monitor for dopamine excess: agitation, insomnia, dyskinesia.
Do not combineCombined stimulant burden overshoots dopaminergic tone. Amphetamines deplete dopamine stores while bromantane increases synthesis: the combination creates unpredictable dopaminergic strain and cardiovascular risk.
Do not combineAdditive dopaminergic stimulation. Bromantane increases synthesis; agonists directly stimulate D2/D3 receptors. Combined effect may cause dysphoria, compulsive behaviors, or cardiovascular strain.
Do not combineEstimated Cost
Pricing updated 2026-04-09
Bromantane (Ladasten) Side Effects
The biggest safety gap with bromantane is the absence of long-term controlled data. The Russian multicenter trial [1] ran for 28 days in 728 patients at 50 to 100 mg daily. Adverse events appeared in roughly 3% of participants. That's a reassuring number, but 28 days tells you nothing about what happens at month three or month six.
Insomnia is the most commonly reported side effect, both in clinical data and across community forums. Bromantane's 8 to 12 hour duration of action means afternoon dosing reliably disrupts sleep. This complaint appears dose-independent; even 25 mg taken too late causes problems. The fix is straightforward: dose before 9:00 AM.
Headache and tension surface mainly above 100 mg. At standard doses (50 to 100 mg), headaches are occasional and generally resolve with hydration. Users pushing to 150 mg report tension headaches as a consistent limiter.
Paradoxical anxiety has been flagged by a subset of community users at doses exceeding 100 mg. The anxiolytic effect inverts in some individuals when dopaminergic tone gets too high. Reducing the dose resolves this.
GI discomfort (loose stools, mild nausea) appears at higher doses. Mild dry mouth is reported intermittently.
Mydriasis (pupil dilation) occurs at standard doses in some users. It's a marker of dopaminergic activity, not a safety concern, but it can cause photosensitivity.
Hepatic strain is a theoretical risk. Bromantane is highly lipophilic and undergoes extensive first-pass hepatic metabolism. It accumulates in adipose tissue throughout a cycle. Liver enzymes (ALT, AST, GGT) should be checked at baseline and at the end of each 4-week cycle, particularly at the 100 mg dose. Any elevation beyond 2x the upper limit of normal warrants stopping.
The compound's lipophilicity also means metabolites (primarily 6-beta-hydroxybromantane) remain detectable in urine for up to two weeks after a single dose. WADA lists bromantane as a non-specified stimulant (S6.A), prohibited in competition. Athletes under WADA rules can't have it in their system at events.
Skin rash is listed in available data but frequency is unclear.
Pregnancy and breastfeeding: no reproductive safety data exists. Children under 18 have not been studied. Anyone with severe hepatic impairment, known hypersensitivity to adamantane-class compounds, or active psychotic disorders should avoid bromantane.
Stop use and consult a physician if you experience persistent insomnia despite early dosing, skin rash, mood instability, or any signs of liver strain.
Common Issues & Solutions
Insomnia: Take no later than 8:00-9:00 AM. The 8-12 hour activity window is dose-independent: afternoon dosing consistently disrupts sleep. If morning-only dosing still causes insomnia, reduce to 25 mg.
No noticeable effects in week 1: Expected: TH/AAAD genomic upregulation takes 5-7 days of consistent dosing. Do not increase dose based on week-1 assessment; wait until week 2 to evaluate.
Headache or tension: Most common above 100 mg. Reduce to 50-75 mg. Ensure adequate hydration. Headache at 50 mg indicates individual sensitivity: taper to 25 mg.
Paradoxical anxiety: Reported by some users at doses above 100 mg. Reduce dose immediately. Bromantane's anxiolytic effects can invert in sensitive individuals at high dopaminergic tone.
Mydriasis (pupil dilation): Documented at standard doses. No clinical action required, but relevant if photosensitivity is an issue. Indicates dopaminergic activity and does not warrant stopping.
Ask AI about this page
Ask AI for a second opinion on Bromantane (Ladasten) dosing and side effects
Contraindications
- Pregnancy or breastfeeding: no reproductive safety data in humans
- Children and adolescents under 18: not studied in pediatric populations
- Severe hepatic impairment: bromantane undergoes extensive hepatic metabolism and is highly lipophilic
- Known hypersensitivity to adamantane-class compounds (amantadine, memantine, rimantadine)
- Active psychotic disorders: dopamine upregulation could theoretically worsen symptoms
- Competitive athletes subject to WADA testing: bromantane is a non-specified stimulant on the 2026 Prohibited List (S6.A), prohibited in competition
- Concurrent use of MAO inhibitors: potential for excessive dopaminergic activity
Drug Interactions
- MAO inhibitors (selegiline, phenelzine, tranylcypromine): bromantane increases dopamine synthesis; combined with MAO inhibition this could produce excessive dopaminergic stimulation
- Levodopa/carbidopa: additive dopamine-enhancing effects; monitor for signs of dopamine excess (agitation, insomnia, dyskinesia)
- Dopamine agonists (pramipexole, ropinirole): potential for additive dopaminergic stimulation
- Benzodiazepines: bromantane has GABA-ergic effects that may potentiate sedation at higher doses, though at normal doses the interaction is likely minimal
- CYP450 substrates: bromantane undergoes hepatic hydroxylation; potential for competition with drugs metabolized by the same enzymes (specific CYP isoforms not fully characterized)
- Other stimulants (caffeine, modafinil, amphetamines): stacking with bromantane may overshoot dopaminergic tone; use caution
Product Quality
Oral compound sold as unregulated research powder or capsule. No FDA oversight of manufacturing quality, potency, or purity. Mislabeled or underdosed product is the primary risk. Bromantane is not injectable, eliminating contamination/sterility concerns, but powder purity variance affects dosing accuracy. Chinese bulk supply chains dominate the market. Adulteration is a theoretical risk given the price point.
- Third-party COA benchmark: HPLC purity data showing at least 98% purity.
- Weigh powder doses on a milligram-accurate scale (0.001 g resolution). A kitchen scale is insufficient for 25-50 mg doses.
- Pre-measured capsule products reduce dosing error risk for those without precision scales.
- Avoid online marketplace listings: frequent mislabeling and no purity guarantees.
- A batch-specific COA is the only record of what a given lot contains; a product without one has unknown purity.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Liver enzymes (ALT, AST, GGT) | Baseline before first cycle; end of each 4-week cycle | ALT <35 U/L, AST <40 U/L (lab-dependent); increase >2x ULN warrants cessation |
| Sleep quality tracking (diary or wearable) | Daily throughout cycle | Not listed |
| WADA detection window planning | Prior to any in-competition period | Not listed |
Bromantane is highly lipophilic with extensive hepatic metabolism. Accumulation in hepatic tissue creates theoretical hepatotoxicity risk with repeated cycling, particularly at 100 mg/day.
Insomnia is the most common adverse effect and earliest indicator of dosing problems (too late in day, too high a dose). Objective tracking is more reliable than self-report.
Bromantane and its metabolite (6-beta-hydroxybromantane) are detectable in urine for up to 2 weeks after a single dose due to slow adipose release. Athletes must stop at minimum 2 weeks before competition; this is not a guarantee of clearance.
Bromantane (Ladasten) Before and After
Subtle effects may begin within hours of the first dose as TH upregulation kicks in. Most users report a gentle lift in mood and motivation without obvious stimulation. Some notice reduced background anxiety. Effects are mild as the genomic mechanism is still ramping up.
Dopamine synthesis upregulation reaches meaningful levels with consistent daily dosing. Users typically report improved focus, mental clarity, and a sense of calm drive. Physical stamina may start to improve. The combination of stimulant and anxiolytic effects becomes more apparent.
Peak effects for most users. Sustained improvements in motivation, cognitive stamina, and stress tolerance. Some report improved verbal fluency and task initiation. Physical endurance benefits are more noticeable. BDNF-related neuroplasticity effects may begin contributing.
Final week of a standard cycle. Benefits should be well-established. Begin planning the off-cycle period. Some users taper to 25-50 mg for the last few days rather than stopping abruptly, though there's no clinical data mandating a taper.
Effects taper gradually over 3-7 days due to tissue accumulation. Metabolites remain detectable in urine for up to two weeks. Most users don't report a significant rebound or withdrawal. Maintain any cognitive habits or routines established during the cycle.
What to Expect
Days 1 to 3 (Genomic Priming): TH upregulation starts within 1.5 to 2 hours of the first dose, based on animal data. But meaningful dopamine increases take repeated dosing to build. Most users notice subtle changes at best, maybe a gentle mood lift or reduced background anxiety. Some feel nothing. That's expected, and increasing the dose at this point won't help.
Days 4 to 7 (Dopamine Synthesis Ramp): Consistent daily dosing brings TH and AAAD enzyme levels to functional upregulation. This is when the effects click for most people. Improved focus, calm energy, better task initiation. Physical stamina starts climbing. The community consensus is clear: evaluate bromantane here, not in the first three days. Insomnia remains the most common complaint; GI changes are occasionally reported.
Weeks 2 to 3 (Peak Effect Window): Full enzyme upregulation is maintained. BDNF and NGF expression may be rising (animal models). The Russian multicenter trial peaked at this timeframe. Users report the strongest motivation, cognitive stamina, and stress tolerance here. Verbal fluency and task follow-through improve. Physical endurance benefits become more obvious. Side effects are minimal at correct dosing and timing. Headache at higher doses and paradoxical anxiety occasionally appear at this stage.
Week 4 (Cycle Completion): Benefits hold steady. Lipophilic accumulation in adipose tissue has been building throughout the cycle. Some users drop to 50 mg for the last few days. Begin planning the off-cycle period. No new side effects are expected.
Off-Cycle Weeks 1 to 3 (Tissue Clearance): Bromantane releases slowly from fat stores. The primary metabolite (6-beta-hydroxybromantane) stays detectable in urine for up to two weeks. Effects taper over 3 to 7 days, not overnight. Most users don't report rebound or withdrawal. The habits and routines built during the cycle tend to stick.
Detailed Timeline: Science vs Community
TH upregulation begins within 1.5-2 hours of first dose (animal data). Dopamine synthesis increases are gradual: enzyme upregulation requires repeated dosing to reach meaningful levels.
Subtle mood lift and reduced background anxiety noted by some. Most report minimal effects. A few notice improved motivation within 24-48 hours.
TH and AAAD enzyme levels reach functional upregulation with consistent daily dosing. Dopamine production meaningfully elevated above baseline.
Improved focus, calm energy, better task initiation. Physical stamina improving. Community consensus: evaluate effects here, not in days 1-3.
Full TH/AAAD upregulation maintained. BDNF and NGF expression potentially elevated (animal models). Russian trial showed peak CGI-I improvement by day 28.
Peak motivation, cognitive stamina, stress tolerance. Improved verbal fluency and task follow-through. Physical endurance benefits more pronounced. Primary benefit window for most users.
Effects well-established. Russian trial endpoint at 28 days. Lipophilic accumulation in adipose tissue is occurring throughout the cycle.
Benefits maintained. Some users taper to 50 mg for the final 3-4 days. Begin planning off-cycle.
Slow release from adipose stores. Primary metabolite (6-beta-hydroxybromantane) detectable in urine for up to 2 weeks post-cessation. Effects taper 3-7 days after last dose.
Gradual return to baseline. No significant rebound or withdrawal. Most users maintain behavioral habits established during cycle.
Pharmacokinetics
Source: Half-life 11.21 hours and peak at 2-4 hours, per the Russian Ladasten label. Metabolites (primarily 6-beta-hydroxybromantane) detectable in urine for up to 2 weeks due to slow release from adipose tissue storage. Oral bioavailability ~42% (Oliynyk and Oh 2012, PMID 24009833).
Pharmacokinetics: Active Dose Over Time
t½ = ~11 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Is Bromantane (Ladasten) Legal?
Bromantane is not approved by the FDA for any indication. No US application for it appears in Drugs@FDA. Russia registered it as Ladasten in 2008 (certificate LSR-010257/08) for asthenic conditions and neurasthenia. It is sold there by prescription.
In the United States, bromantane is sold as a research compound. It's not a controlled substance under the Controlled Substances Act, but it has no regulatory pathway for human therapeutic use. It cannot be marketed for human consumption.
WADA lists bromantane as a non-specified stimulant (S6.A) on the 2026 Prohibited List. Like every S6 stimulant, it is prohibited in competition. Metabolites are detectable in urine for up to two weeks after a single dose. WADA's in-competition period generally starts at 11:59 p.m. the day before a competition and runs until the competition and its sample collection end. A dose taken days before that window can still show up in the test.
Bromantane is not available through US compounding pharmacies, as it is not an approved compounding ingredient.
This content is for educational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research compound.
Evidence grade: Approved outside the US (Peptide Evidence Gap, October 2026)
Who Should Consider Bromantane (Ladasten)
- Adults seeking non-stimulant cognitive and motivational support (research context)
- Individuals with neurasthenia or chronic asthenic conditions (approved in Russia)
- Researchers studying dopamine biosynthesis upregulation mechanisms
- Those investigating anxiolytic compounds without benzodiazepine-class risks
- Athletes subject to WADA testing should NOT use: WADA prohibits bromantane in competition
Related Peptides
What Changed for Bromantane (Ladasten)
- Regulatory
Corrected Oct 15, 2026: bromantane's status section drops the state-legality claim and the IND wording; no application for it is listed, per Drugs@FDA.
What this does not mean: Nothing changed at FDA. IND filings are not public, so the old 'no active IND' line could not be checked, and no state-by-state survey backed the purchase claim.
Source: Drugs@FDA (openFDA) search for active ingredient BROMANTANE: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy
- Regulatory
Corrected Oct 15, 2026: bromantane now carries a sourced US status: no US application in Drugs@FDA and no federal schedule, per Drugs@FDA.
Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; absent from 21 CFR 1308, the DEA list and the 503A and 503B category lists
What this does not mean: Russian registration as Ladasten stays in the page text only; its state-register record is not captured. Nothing changed at FDA or DEA, and WADA still lists it as a non-specified stimulant (S6.A).
Source: Drugs@FDA (openFDA) search for active ingredient BROMANTANE: no matches, retrieved Oct 15, 2026 (opens in a new tab) · Saved copy
- Safety
Corrected Oct 15, 2026: Bromantane's side effects now say WADA lists it as a non-specified stimulant (S6.A), prohibited in competition, per WADA's 2026 list.
Before: Called bromantane a specified stimulant under category S6 After: Non-specified stimulant (S6.A) on the 2026 Prohibited List, prohibited in competition
What this does not mean: WADA did not reclassify bromantane in 2026. The page named the wrong S6 subclass and said it was prohibited out of competition too; S6 applies in competition only.
Source: World Anti-Doping Agency, 2026 Prohibited List (in effect Jan 1, 2026), S6.A Non-Specified Stimulants (opens in a new tab) · Saved copy
- Safety
Corrected Oct 15, 2026: Bromantane's athlete warning now gives WADA class S6.A, a non-specified stimulant prohibited in competition, per WADA's 2026 list.
Before: Athletes item said bromantane is a specified stimulant on the Prohibited List (S6) After: Athletes item says non-specified stimulant on the 2026 Prohibited List (S6.A), prohibited in competition
What this does not mean: The advice to athletes is unchanged: bromantane is on the Prohibited List. Only the subclass and the in-competition scope were corrected.
Source: World Anti-Doping Agency, 2026 Prohibited List (in effect Jan 1, 2026), S6.A Non-Specified Stimulants (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Sep 24, 20269 Citations
References
- [1]Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten (Zh Nevrol Psikhiatr 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (Neuropharmacology 2007) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance (Biomol Ther (Seoul) 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Cytosine demethylation in the tyrosine hydroxylase gene promoter in rat hypothalamus cells under ladasten (Vakhitova et al., Genetika 2006) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Mechanisms of action of ladasten: activation of gene expression for neurotrophins and mitogen-activated kinases (Salimgareeva et al., Bull Exp Biol Med 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Ladasten, a new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia: results of comparative clinical study with placebo (Zh Nevrol Psikhiatr 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) (Br J Pharmacol 2008) (opens in a new tab)PubMed 18500382PubMed
- World Anti-Doping Agency, 2026 Prohibited List: bromantan under S6.A (non-specified stimulants), prohibited in competition; the in-competition period is defined in the introduction (opens in a new tab)Review
- Vidal: Ladasten, prescription only, previous registration certificate LSR-010257/08 (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Bromantane (Ladasten)?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
5 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.